Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00516217 · ClinicalTrials.gov registry record · Phase 2

Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

A Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
20
Study locations

NCT00516217 is a Phase 2 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 30 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00516217, a Phase 2 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Monoclonal antibodies, such as galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase II trial is studying how well galiximab works in treating patients with relapsed or refractory Hodgkin's lymphoma.

Conditions Studied

Lymphoma

Interventions

  • BIOLOGICAL galiximab

Study Locations (20)

Illinois

  • St. Joseph Medical Center - Bloomington
  • Graham Hospital - Canton
  • Memorial Hospital - Carthage
  • University of Chicago Cancer Research Center - Chicago
  • Eureka Community Hospital - Eureka
  • Galesburg Clinic, PC - Galesburg
  • Galesburg Cottage Hospital - Galesburg
  • Mason District Hospital - Havana
  • Hopedale Medical Complex - Hopedale
  • McDonough District Hospital - Macomb
  • BroMenn Regional Medical Center - Normal
  • Community Cancer Center - Normal
  • Community Hospital of Ottawa - Ottawa
  • Oncology Hematology Associates of Central Illinois, PC - Ottawa - Ottawa
  • Cancer Treatment Center at Pekin Hospital - Pekin
  • Proctor Hospital - Peoria
  • CCOP - Illinois Oncology Research Association - Peoria

Delaware

  • Tunnell Cancer Center at Beebe Medical Center - Lewes
  • CCOP - Christiana Care Health Services - Newark

District of Columbia

  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-06
Est. Completion 2015-02
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00516217

The ClinicalTrials.gov registry entry for NCT00516217 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (94% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which galiximab is the first listed.

NCT00516217 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Delaware, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00516217 about?

NCT00516217 is a clinical study titled "Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies, such as galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase II trial is studying how well galixi...

What is the current status of trial NCT00516217?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-06. Estimated completion is 2015-02.

What conditions does trial NCT00516217 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT00516217?

The interventions under investigation include: galiximab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00516217?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00516217 being conducted?

This trial has 20 study locations across Delaware, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Delaware

All trials with a study site in Delaware

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.